Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERASURE: Secukinumab in Moderate to Severe Plaque Psoriasis
NCT01365455Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2011
- Primary completion
- Apr 2013
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of secukinumab in plaque psoriasis, sponsored by Novartis. Started Jun 2011; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01365455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01365455.